Barclays analyst Gena Wang maintained a Hold rating on Bluebird Bio (BLUE - Research Report) on August 18 and set a price target of $7.00. The company's shares closed yesterday at $5.97.According to TipRanks, Wang is a 5-star analyst with an average return of 14.5% and a 48.69% success rate. Wang covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Alnylam Pharma, and BioCryst.Bluebird Bio has an analyst consensus of Hold, with a price target consensus of $6.83, which is a 14.41% upside from current levels. In a report released on August 18, SVB Securities also maintained a Hold rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-hold-rating-for-bluebird-bio-blue?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more bluebird bio Charts.